search
Back to results

EndoClot for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection (EMR)

Primary Purpose

Endoscopic Hemostasis, Colonic Polyps

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Hemoclip
EndoClot
Sponsored by
Xijing Hospital of Digestive Diseases
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endoscopic Hemostasis focused on measuring Endoscopic Hemostasis, metallic hemoclip, EndoClot Absorbable Polysaccharide Hemostat, Colonic Polyps

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • consecutive cases of colorectal polyps and submucosal tumors with anticipated complete removal endoscopically by EMR.

Exclusion Criteria:

  • severe cardiovascular diseases, liver and kidney dysfunction;
  • platelet and coagulation dysfunction (PLT < 50*109/L, INR > 2);
  • cases that have taken anticoagulant drugs or non-steroidal anti-inflammatory drugs within 1 month before the procedure;
  • cases unavailable for follow-up.

Sites / Locations

  • Xijing Hospital of Digestive Diseases

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

EndoClot

Hemoclip

Arm Description

This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.

This arm is used as a control treatment group to compare with Endoclot treatment.

Outcomes

Primary Outcome Measures

Hemostasis rate after EMR
Initial hemostatsis was observed endoscopically immediately after application of hemoclip or Endoclot. Complete hemostatsis is ensured. Endoscopic combined hemostasis or emergency surgery would be applied if severe bleeding occurred and endoscopic management fails

Secondary Outcome Measures

Mucosal healing after EMR
Colonoscopy will be repeated 1 month after EMR procedure to observe if application of Endoclot will delay the musosal healing.
Time taken to achieve hemostasis
The time taken to achieve hemostasis is recorded immediately after EMR procedure to reflect the technical difficulty of hemostasis measure.
Rebleeding rate after EMR procedure
Rebleeding rate up to 1 week was obtained by clinical manifestations such as melana; decreased hemoglobin > 20g/L; hemodynamic instability or active bleeding from mucosal defect under endoscope.
gastrointestinal tract obstruction
Gastrointestinal tract obstruction has been previously reported as a possible adverse effect of hemostats, therefore it was observed in the current study.

Full Information

First Posted
December 19, 2011
Last Updated
April 14, 2012
Sponsor
Xijing Hospital of Digestive Diseases
search

1. Study Identification

Unique Protocol Identification Number
NCT01496781
Brief Title
EndoClot for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection
Acronym
EMR
Official Title
EndoClotTM Absorbable Polysaccharide Hemostat in Comparison With Metallic Hemoclip for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection: a Prospective, Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Xijing Hospital of Digestive Diseases

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment techniques of gastrointestinal small lesions. Para-procedure bleeding is one of the common complication following EMR. Several endoscopic hemostasis methods are currently in use including metallic hemoclip. EndoClot® absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic application remains unknown. This randomized controlled study has been designed to compare PAPH with metallic hemoclip in their hemostatic effect of intra-procedure bleeding control and rebleeding prevention during and after EMR.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endoscopic Hemostasis, Colonic Polyps
Keywords
Endoscopic Hemostasis, metallic hemoclip, EndoClot Absorbable Polysaccharide Hemostat, Colonic Polyps

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
164 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EndoClot
Arm Type
Experimental
Arm Description
This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
Arm Title
Hemoclip
Arm Type
Active Comparator
Arm Description
This arm is used as a control treatment group to compare with Endoclot treatment.
Intervention Type
Procedure
Intervention Name(s)
Hemoclip
Other Intervention Name(s)
metallic hemoclip (Cat# HX-610-090L, Olympus)
Intervention Description
Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
Intervention Type
Procedure
Intervention Name(s)
EndoClot
Other Intervention Name(s)
EndoClot® Absorbable Polysaccharide Hemostat (Cat# Y2007090722, Starch Medical Inc)
Intervention Description
EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Primary Outcome Measure Information:
Title
Hemostasis rate after EMR
Description
Initial hemostatsis was observed endoscopically immediately after application of hemoclip or Endoclot. Complete hemostatsis is ensured. Endoscopic combined hemostasis or emergency surgery would be applied if severe bleeding occurred and endoscopic management fails
Time Frame
Up to half an hour immediately after EMR procedure to ensure successful management is achieved.
Secondary Outcome Measure Information:
Title
Mucosal healing after EMR
Description
Colonoscopy will be repeated 1 month after EMR procedure to observe if application of Endoclot will delay the musosal healing.
Time Frame
up to 1 month
Title
Time taken to achieve hemostasis
Description
The time taken to achieve hemostasis is recorded immediately after EMR procedure to reflect the technical difficulty of hemostasis measure.
Time Frame
Up to half an hour immediately after EMR procedure to ensure successful management is achieved.
Title
Rebleeding rate after EMR procedure
Description
Rebleeding rate up to 1 week was obtained by clinical manifestations such as melana; decreased hemoglobin > 20g/L; hemodynamic instability or active bleeding from mucosal defect under endoscope.
Time Frame
up to 1 week
Title
gastrointestinal tract obstruction
Description
Gastrointestinal tract obstruction has been previously reported as a possible adverse effect of hemostats, therefore it was observed in the current study.
Time Frame
up to 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: consecutive cases of colorectal polyps and submucosal tumors with anticipated complete removal endoscopically by EMR. Exclusion Criteria: severe cardiovascular diseases, liver and kidney dysfunction; platelet and coagulation dysfunction (PLT < 50*109/L, INR > 2); cases that have taken anticoagulant drugs or non-steroidal anti-inflammatory drugs within 1 month before the procedure; cases unavailable for follow-up.
Facility Information:
Facility Name
Xijing Hospital of Digestive Diseases
City
Xi'an
State/Province
Shaanxi
ZIP/Postal Code
710032
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
10625793
Citation
Parra-Blanco A, Kaminaga N, Kojima T, Endo Y, Uragami N, Okawa N, Hattori T, Takahashi H, Fujita R. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest Endosc. 2000 Jan;51(1):37-41. doi: 10.1016/s0016-5107(00)70384-1.
Results Reference
background
PubMed Identifier
11480327
Citation
Lin LF, Siauw CP, Ho KS, Tung JC. Endoscopic hemoclip treatment of gastrointestinal bleeding. Chang Gung Med J. 2001 May;24(5):307-12.
Results Reference
background
PubMed Identifier
8491134
Citation
Binmoeller KF, Thonke F, Soehendra N. Endoscopic hemoclip treatment for gastrointestinal bleeding. Endoscopy. 1993 Feb;25(2):167-70. doi: 10.1055/s-2007-1010277.
Results Reference
background
PubMed Identifier
16082303
Citation
Katsinelos P, Paroutoglou G, Beltsis A, Papaziogas B, Gouvalas A, Chatzimavroudis G, Vlachakis I, Mimidis K, Vradelis S, Pilpilidis I. Endoscopic hemoclip application in the treatment of nonvariceal gastrointestinal bleeding: short-term and long-term benefits. Surg Laparosc Endosc Percutan Tech. 2005 Aug;15(4):187-90. doi: 10.1097/01.sle.0000174575.52840.23.
Results Reference
background
PubMed Identifier
19430833
Citation
Kouklakis G, Mpoumponaris A, Gatopoulou A, Efraimidou E, Manolas K, Lirantzopoulos N. Endoscopic resection of large pedunculated colonic polyps and risk of postpolypectomy bleeding with adrenaline injection versus endoloop and hemoclip: a prospective, randomized study. Surg Endosc. 2009 Dec;23(12):2732-7. doi: 10.1007/s00464-009-0478-3. Epub 2009 May 9.
Results Reference
background
PubMed Identifier
21782216
Citation
Wang Y, Xu M, Dong H, Liu Y, Zhao P, Niu W, Xu D, Ji X, Xing C, Lu D, Li Z. Effects of PerClot(R) on the healing of full-thickness skin wounds in rats. Acta Histochem. 2012 Jul;114(4):311-7. doi: 10.1016/j.acthis.2011.06.012. Epub 2011 Jul 22.
Results Reference
background

Learn more about this trial

EndoClot for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection

We'll reach out to this number within 24 hrs